ARB/ACEI group had significantly lower concentrations of CRP and PCT  ARB/ACEI group had a lower non-significant proportion of critical patients, and death rate  This study supports the use of ARBs/ACEIs in COVID-19 patients with preexisting HT. This evidence concerns the gene CRP and hematocrit.